Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Wk, Phase 3, Open Label (OL) Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period and an OL Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in CKD Patients on Dialysis

NCT03427125 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT03427125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03427125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Wk, Phase 3, Open Label (OL) Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period and an OL Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in CKD Patients on Dialysis
Lead sponsor
Ardelyx
Phase
Phase 3
Overall status
Completed
Start date
January 8, 2018
Completion date
February 27, 2020
Enrollment
1,559 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia